Extracellular nanobody screening using conformationally stable GPCR variants
Open Access
- 4 November 2025
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (45)
Abstract
G protein–coupled receptors (GPCRs) are prominent drug targets that have attracted intensive efforts in drug screening. Binding-based screening methods for GPCR ligands often require conformationally stable, purified receptors. However, obtaining large quantities of GPCRs in stable states, particularly with unoccupied extracellular ligand-binding pockets and especially in their active conformations, remains challenging due to the inherent dynamic nature of these receptors. To address this challenge, we propose a universal approach for stabilizing GPCRs in specific conformations. Using the M1 muscarinic acetylcholine receptor (M1R) as a model, we successfully stabilized M1R in its active conformation through de novo design of a fusion protein, and further demonstrated the generalizability of this strategy by applying it to other GPCRs. We screened a synthetic yeast display library of nanobodies against both the stabilized active-state and previously reported inactive-state M1R, identifying several nanobodies that specifically recognize each conformation. This method not only facilitates the stabilization of GPCRs in desired states but also provides valuable tools for developing more selective therapeutic agents, enhancing drug discovery efficiency and specificity.Keywords
Funding Information
- National Natural Science Foundation of China (Grant 32122041)
This publication has 58 references indexed in Scilit:
- Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trialThe Lancet, 2023
- UCSF ChimeraX : Tools for structure building and analysisProtein Science, 2023
- From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimer’s diseaseCell, 2021
- Discovery of the Migraine Prevention Therapeutic Aimovig (Erenumab), the First FDA-Approved Antibody against a G-Protein-Coupled ReceptorACS Pharmacology & Translational Science, 2019
- Structural Insights into the Process of GPCR-G Protein Complex FormationCell, 2019
- Nanobodies: New avenues for imaging, stabilizing and modulating GPCRsMolecular and Cellular Endocrinology, 2019
- Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseasesNeuropharmacology, 2018
- Structural Insights into the Dynamic Process of β2-Adrenergic Receptor SignalingCell, 2015
- Crystal structure of opsin in its G-protein-interacting conformationNature, 2008
- Automated acquisition of cryo-electron micrographs for single particle reconstruction on an FEI Tecnai electron microscopeJournal of Structural Biology, 2005